# Study Compares Long-Term Efficacy of Common Antidepressants New research suggests specific medications may sustain symptom relief better than others over time. - **Source:** [The Conversation – Australia](https://theconversation.com/au) - **Published:** 2026-11-11 - **Topic:** [health](https://brifing.si/c/health) - **Original article:** - **On Brifing:** https://brifing.si/s/d03856ea-ea44-4c2f-9850-272d69953f5d ## Comparative Efficacy Findings A recent review published in The Lancet Psychiatry analyzed 115 randomized controlled trials involving over 30,000 participants. The study suggests that escitalopram, duloxetine, and agomelatine may be more effective at sustaining symptom relief than fluoxetine. These findings provide new insights into how different antidepressants perform for patients over the long term. ## Medication Adherence Metrics Researchers measured treatment acceptability by tracking patient drop-out rates during the study periods. Individuals prescribed escitalopram and duloxetine were less likely to discontinue their medication compared to those taking fluoxetine. This suggests that these specific drugs might be more tolerable for patients who require ongoing treatment for their depressive symptoms. ## Defining Long-Term Usage The study defined long-term use as six months or more, though most trials only tracked participants for about six months. This duration is relatively short given that many patients take antidepressants for an average of four years. Consequently, there is still limited data on how these medications compare over several years. ## Context of Australian Prescriptions In 2024-2025, 3.8 million Australians received antidepressant prescriptions, highlighting the scale of usage. Escitalopram remains the most commonly prescribed antidepressant in the country, ranking 13th among all PBS-dispensed medications. Understanding the comparative effectiveness of these drugs is crucial for clinicians managing the high volume of patients requiring long-term mental health support. ## Limitations and Bias Risks The research results are not definitive, as over half of the analyzed studies were assessed as having a high risk of bias. These methodological limitations mean that observed differences between medications might reflect study flaws rather than genuine clinical variations. Furthermore, some drugs were supported by very few trials, reducing overall certainty. ## Individual Treatment Variability These findings represent average outcomes across large groups and cannot predict how a specific individual will respond to a medication. Patient experiences are highly subjective, involving complex trade-offs between symptom improvement, side effects, and daily life impact. What is considered acceptable for one person may not be suitable for another. ## Challenges in Discontinuation Clinical guidelines typically recommend continuing antidepressants for six to 12 months after recovery before considering a gradual reduction. However, many patients remain on medication for years, sometimes due to withdrawal symptoms that make stopping difficult. It is essential that any changes to medication regimens are managed carefully in consultation with doctors. ## Clinical Guidance for Patients Patients currently benefiting from their existing antidepressant should not switch medications based solely on these findings. Choosing the right treatment depends on personal symptoms, health history, and individual goals. Anyone considering starting, changing, or stopping their medication must discuss their specific options with a qualified healthcare provider to ensure safety. ## Sources covering this story - https://theconversation.com/some-antidepressants-may-work-better-than-others-long-term-new-study-296151 — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._